
-
C4 Therapuetics NasdaqGS:CCCC C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Location: 490 Arsenal Way, Watertown, MA, 02472, United States | Website: https://www.c4therapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-56.99M
Cash
215.1M
Avg Qtr Burn
-20.08M
Short % of Float
12.79%
Insider Ownership
9.79%
Institutional Own.
92.06%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cemsidomide (CFT7455) +/- dexamethasone Details Hematologic malignancies, Blood disorder, Non-Hodgkin lymphoma, Blood cancer, Multiple myeloma | Phase 1/2 Data readout | |
CFT1946 (mono) +/- cetuximab Details Cancer, V600 Mutant Cancers, Solid tumor/s, Colorectal cancer, Melanoma | Phase 1/2 Data readout | |
CFT8919 (EGFR) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
CFT8634 (BiDAC) Details Rare diseases, Cancer | Failed Discontinued |